Darzalex-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma Ruchika Sharma22 Sept 2024 12:30 PM ISTBeerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use...
USFDA nod to Sanofi Sarclisa in combo with bortezomib, lenalidomide, dexamethasone for newly diagnosed multiple myeloma not eligible for transpant Ruchika Sharma21 Sept 2024 2:25 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib,...
JnJ gets USFDA nod for Darzalex Faspro-based quadruplet regimen for newly diagnosed multiple myeloma who are transplant-eligible Ruchika Sharma2 Aug 2024 11:30 AM ISTHorsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved DARZALEX FASPRO (daratumumab and...
Blenrep combinations in multiple myeloma application accepted for review by EMA: GSK Ruchika Sharma20 July 2024 3:30 PM ISTLondon: GSK plc has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for...
Sanofi Sarclisa accepted for USFDA priority review for transplant-ineligible newly diagnosed multiple myeloma Ruchika Sharma27 May 2024 11:30 AM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License...
Sanofi multiple myeloma drug Sarclisa phase 3 trial meets primary endpoint of progression-free survival Ruchika Sharma10 Dec 2023 11:30 AM ISTParis: Sanofi has announced that the Phase 3 IMROZ trial evaluating the investigational use of Sarclisa (isatuximab) in combination with...
GSK declares positive results from phase III trial for Blenrep in relapsed/ refractory multiple myeloma Ruchika Sharma28 Nov 2023 12:30 PM ISTLondon: GSK plc has announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial...
Medicamen Biotech files ANDA for Bortezomib for injection with USFDA Ruchika Sharma19 July 2023 4:18 PM ISTNew Delhi: Medicamen Biotech Limited has announced that the company has successfully filed the first ANDA in eCTD format for BORTEZOMIB for...
Janssen seeks USFDA nod for Carvykti for relapsed or refractory multiple myeloma Ruchika Sharma8 Jun 2023 12:30 PM ISTRaritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental Biologics License...
Multiple Myeloma medicine: Natco Pharma unveils Pomalidomide under brand NAT-POMALIDOMIDE in Canada Ruchika Sharma1 March 2023 12:15 PM ISTMultiple myeloma, commonly referred to as myeloma, is a cancer of plasma cells.
Dr Reddy's Labs unveils cancer drug Lenalidomide in US Ruchika Sharma8 Sept 2022 2:47 PM ISTDr. Reddy's Lenalidomide Capsules are available in strengths of 2.5 mg, 5 mg, and 10 mg, each in a bottle-count size of 28, as well as 15 mg, 20 mg,...
Dr Reddys launches Bortezomib for Injection in US Rahul Verma29 July 2022 5:09 PM ISTDrugmaker, Dr Reddy's Laboratories Ltd., has announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade (bortezomib)...
